Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
NAMS compared with PHAT: revenue, margins and what each company keeps, and the suppliers and customers both name
NAMS
NewAmsterdam Pharma Co N.V.
Change
Mkt cap
Revenue
Revenue
PHAT
Phathom Pharmaceuticals, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
NAMS
NewAmsterdam Pharma Co N.V.
vs
PHAT
Phathom Pharmaceuticals, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
NAMS: latest quarter is a loss; flow not drawable. PHAT: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only NAMS
0
None
Shared
0
No disclosed counterparties: NAMS.
Only PHAT
2
—
Takeda Pharmaceutical
unlisted
supplier
—
Sandoz
unlisted
supplier
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
NAMS, solid
PHAT, dashed
NAMS
NewAmsterdam Pharma Co N.V.
Change
19.91
· pre 19.90
· delayed
Mkt cap
$2.4B
Revenue
$4M
Q2 FY26
Revenue
$23M
FY25
PHAT
Phathom Pharmaceuticals, Inc.
Change
5.75
· pre 5.75
· delayed
Pre-market
Nov 4 '26
delayed
Mkt cap
$466.6M
Revenue
$85M
Q3 FY26
Revenue
$175M
FY25
vs
Compare
Pre-market
Nov 4 '26
delayed
NAMS
NewAmsterdam Pharma Co N.V.
vs
PHAT
Phathom Pharmaceuticals, Inc.
19.91
pre 19.90
delayed
Price
5.75
pre 5.75
delayed
$2.4B
Mkt cap
$466.6M
Q2 FY26
$4M
Revenue
$85M
Q3 FY26
FY25
$23M
Revenue
$175M
FY25
Change
Change
NAMS
19.91
vs
PHAT
5.75
Pre-market
Nov 4 '26
delayed